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THERMOTHERAPY EFFECTIVE AND SAFER THAN MILTEFOSINE IN THE TREATMENT OF 
CUTANEOUS LEISHMANIASIS IN COLOMBIA
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SUMMARY
In Colombia, pentavalent antimonials and miltefosine are the drugs of choice for the treatment of cutaneous leishmaniasis; 
however, their toxicity, treatment duration, (treatment adherence problems), cost, and decreased parasite sensitivity make the search for 
alternative treatments of American cutaneous leishmaniasis necessary. Based on the results found in a controlled, open, randomized, 
phase III clinical trial, the efficacy and safety of miltefosine was compared to that of thermotherapy for the treatment of cutaneous 
leishmaniasis in Colombia. Adult patients from the Colombian army participated in the study; they received either 50 mg of miltefosine 
three times per day for 28 days by the oral route (n = 145) or a thermotherapy (Thermomed®) application of 50 ºC for 30 seconds 
over the lesion and surrounding area (n = 149). Both groups were comparable with respect to their sociodemographic, clinical, and 
parasitological characteristics. The efficacy of miltefosine by protocol and by intention to treat was 70% (85/122 patients) and 69% 
(85/145 patients), respectively. The adverse effects were primarily gastrointestinal for miltefosine and pain at the lesion site after 
treatment for thermotherapy. No statistically significant difference was found in the efficacy analysis (intention to treat and protocol) 
between the two treatments. ClinicalTrials.gov: NCT00471705.
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INTRODUCTION
Leishmaniasis is a disease produced by parasites of the genus 
Leishmania; it is transmitted by female insects of the genus Lutzomyia in 
the Americas or Phlebotomus in the Old World, and it affects humans and 
domesticated and wild mammals2,4,17. It is endemic in over 95 countries, 
the majority of which are classified as developing. It is estimated that 
worldwide, around 12 million individuals are infected with Leishmania35. 
Cutaneous Leishmaniasis (CL) is the clinical manifestation presented by 
the majority of cases around the world, and there is approximately 1 to 
1.5 million new cases every year2,17,35. In Colombia, a re-emergence of 
leishmaniasis has been seen since 2005, making the country second in 
the Americas for highest number of cases. From 2005-2008, there were 
61,120 cases diagnosed, of which 34,262 (56.1%) occurred in military 
personnel of the National Army.
Since the 1940’s, pentavalent antimonials (meglumine antimoniate 
and sodium stibogluconate) have been the drug of choice for the 
treatment of CL; however, their toxicity, treatment period of 20 days 
that leads to treatment adherence issues, high cost, and progressively 
decreasing therapeutic response make necessary the search for alternative 
treatments8,27.
In the search for therapeutic alternatives, various oral medications 
have been evaluated, such as dapsone18, ketoconazole12,21, mefloquine9, 
and allopurinol31, none of which were shown to be adequately effective. 
An additional difficulty in the interpretation of results of clinical trials 
is the lack of methodological unity, which hinders their comparison3,8.
Miltefosine (hexadecylphosphocholine) is an oral medication 
initially developed as an anti-tumoral agent28 that later showed in vitro 
and in vivo activity against Leishmania spp5,6,15,28,37. In India, where 
resistance to antimonial agents is very high, miltefosine has been used 
since 1998 for the treatment of Visceral Leishmaniasis (VL) produced 
by L. donovani7,24. This has motivated its evaluation for the treatment 
of other leishmaniasis25. In Colombia, two studies have been conducted 
for the treatment of CL. The first is a phase I-II study with a reported 
cure rate by protocol of 66% in individuals who received a dose of 50-
100 mg/day and of 95% in individuals who received a dose of 133-150 
mg/day23. The second study was a multicenter study (Colombia and 
Guatemala) where miltefosine was compared against a placebo; this 
study showed contradictory results. In Colombia, the cure rate by protocol 
was 91%, but in Guatemala, the rate was 53%. Even though the sample 
size was small and the number of strains very small, the difference in 
the therapeutic response between both countries was attributed to the 
predominant Leishmania species of each country: Leishmania (Viannia) 
panamensis in Colombia, but L. (V.) braziliensis and L. (L.) mexicana 
in Guatemala. However, recent studies conducted in Colombia show 
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that L. (V.) braziliensis and L. (V.) panamensis are the two species that 
produce the majority of cases in Colombia and that they occur in a similar 
proportion; however, L. (V.) panamensis predominates in the northeast 
of the country (Andean region) and L. (V.) braziliensis predominates in 
the southeast (PECET. Unpublished data). Based on the previous study, 
the Ministry of Social Security of Colombia authorized the registry and 
use of miltefosine, and it has been used for the treatment of different 
clinical forms of leishmaniasis.
On the other hand, studies conducted in different countries have 
shown that the localized application of heat by using Thermomed® 
equipment may achieve a cure rate that varies from 70 to 94%. The 
Thermomed® is an operator, with special devices which achieve and 
maintain a temperature of 50 ºC. The electrodes are placed locally in 
the lesion for 30 seconds, the device produces heat waves through radio 
frequency technology, which extends them to deeper layers of the skin, 
causing destruction of the amastigotes10,11,16,19,30. In Colombia, there has 
only been one report of the use of thermotherapy in the treatment of 
CL in a study that focused on patients with an L. guyanensis from the 
Andean region; however, the elevated number of participant follow-up 
losses (81%) decreased the power of the study and did not allow for a 
conclusive efficacy result29.
This data analysis from a controlled phase III clinical trial was 
conducted with the aim of comparing the efficacy and safety of 
miltefosine with that of a single thermotherapy application in the 
treatment of CL in Colombia. The trial evaluated the efficacy and safety 
of miltefosine and thermotherapy as compared to meglumine antimoniate 
for the treatment of cutaneous leishmaniasis.
MATERIALS AND METHODS
Study design. The study was an open, randomized, phase III clinical 
trial, in which the efficacy and safety of miltefosine and thermotherapy 
were compared. Register ClinicalTrials.gov: code number NCT00471705.
Population and study site. The study was conducted between June 
2006 and April 2008. The study subjects were adult males who were 
part of the Colombian army. The study was conducted at five military 
health care establishments located in the northeast, center, and south of 
Colombia. 
Inclusion criteria. Patients who were included had: a) a confirmed 
parasitological diagnosis of leishmaniasis; b) no previous history 
of receiving treatment for the current infection; c) normal renal, 
hepatic, pancreatic, and hematologic tests; and d) voluntarily accepted 
participation in this study. 
Exclusion criteria. Patients with a) serious concomitant diseases; 
b) lesions with mucosal involvement; c) 10 or more cutaneous lesions 
and a negative Montenegro test; and/or d) cutaneous lesions located less 
than 2 cm from the nasal, oral, lip border, eyes, urogenital orifice, and/
or anal mucosa.
Interventions. Miltefosine (Impavido®, Zentaris Frankfurt-Germany) 
in a 50 mg capsule was administered orally three times per day after 
meals for 28 days for a total dose of 4,200 mg per patient. A single 
thermotherapy (Thermomed®, Thermosurgery inc. Phoenix-USA) session 
was administered, consisting of applications at 50 ºC over the lesion and 
surrounding areas for 30 seconds with prior asepsis and local 2% lidocaine 
anesthesia without epinephrine. The number of applications depended 
on the lesion size, and each time, heat was applied to the entire lesion 
area. Following thermotherapy, an antibiotic ointment (fucidic acid) was 
applied to the lesions and dressed with sterile gauze to prevent secondary 
infections over the next 10 days. 
Data collection, clinical samples, and strain identification of 
Leishmania. After signing voluntary participation consent, all of the 
patients were assigned a clinical record with demographic information, 
lesion data, and review of inclusion/exclusion criteria. A photographic 
registry of all the lesions was obtained, and clinical samples were taken 
for the identification of Leishmania species via PCR-RFLP, following 
previously published protocols13,20. 
Treatment group assignment. Assignment to each treatment group 
was randomized. A list of randomly generated treatments, in blocks of 
eight, was made (EpiInfo 3.1). Only the study coordinator had access to 
the list and was in charge of assigning the treatments.
Follow-up and outcome. During the study, the participants who 
received miltefosine were evaluated by research personnel at the 
beginning, middle (day 15), and end of treatment (day 29), as well as 
six weeks, three months, and six months post treatment. Patients who 
received thermotherapy were evaluated at the beginning, day 10, and day 
20, as well as six weeks, three months, and six months post treatment. 
Renal, hepatic, pancreatic, and hematologic function tests were obtained 
before treatment, in the middle, and at the end of treatment. Evaluation of 
adverse events was conducted based on the usual criteria for the evaluation 
of adverse reactions in cancer therapy v.3 (CTCAE)26.
Response to treatment was clinically evaluated. The following 
definitions were used for each lesion:
Initial cure: Complete re-epithelization of all ulcers and the complete 
disappearance of induration up to three months following the termination 
of treatment.
Definitive cure: Initial cure plus the absence of recurrence at six 
months after completing treatment.
Treatment failure: a) Increase in lesion size greater than 50% by the 
end of treatment; b) Absence of clinical response at six weeks, which 
is a decrease in the lesion area to less than 50% upon final treatment 
evaluation; c) any sign of lesion activity at three months after completing 
treatment; or d) development of mucosal leishmaniasis (ML).
Relapse: Reactivation of the lesion at the original site after scar 
formation.
Rescue therapy for all participants who experienced treatment failure 
was the administration of meglumine antimoniate (Glucantime® , Aventis, 
Paris, France) with a dose of 20 mg/Sb5/K/d for 20 days, as established 
by MOH Colombia guidelines. 
Statistical analysis: Data entry and analysis were performed using 
ACCESS and SPSS version 15, respectively. Participant characteristics 
were tabulated and analyzed by treatment group. The efficacy of 
treatments was calculated by intention to treat and by protocol. The 
relative risk was calculated using 2 x 2 tables. The X2 test or Fisher’s 
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exact test were used for hypothesis testing on dichotomous variables. 
Taking into account the distribution of variables, the Student’s t-test or 
Mann-Whitney U-test were used to analyze continuous data. Potential 
confounding factors and interactions were controlled using a stratified 
analysis of species of the parasite responsible for the infection, number, 
anatomical location, type of lesion, and geographical location of the 
infection. Survival analysis methods (Kaplan-Meier and Log-rank test) 
were used to compare disease-free times between the two treatments. A 
p < 0.05 was considered significant for all analyses, and a confidence of 
95% was used for the construction of all intervals.
RESULTS
There were 294 patients who accepted voluntary participation 
and were included in the study and randomly assigned; 145 received 
miltefosine and 149 received thermotherapy. In the miltefosine group, 
two patients (1%) did not complete treatment due to side effects, and 21 
(14%) were lost by the 6-month follow-up; for this reason, at the end, 
only 122 (84%) completed the study. In the thermotherapy group, two 
patients (1%) decided not to participate in the study after randomization, 
18 (13%) were lost by the 6-month follow-up, and 134 (90%) completed 
the study (Fig. 1). 
Baseline analysis: As observed in Table 1, the demographic, clinical, 
and parasitological characteristics of the participants were similar 
between both study groups, except for type of lesion. 
Therapeutic response
Initial cure: Three months after completion of treatment, 98 (68.5%) 
and 93 (63.2%) of the patients treated with miltefosine and thermotherapy 
were cured, respectively.
Definitive cure: the number of patients who were cured is shown in 
Table 2, which is organized by treatment and by type of analysis.
At six months after completion of treatment, 85 (69.5%) and 86 
(64.5%) of the volunteers receiving miltefosine and thermotherapy, 
respectively, had a complete cure from all lesions (analysis by protocol). 
By intention to treat, the efficacy was 59.4% for the group that received 
miltefosine and 58.5% for the group treated with thermotherapy. There 
were not found differences between the scars of patients who received 
miltefosine or thermotherapy.
Analysis by group: In 164 (56%) patients, the Leishmania species 
responsible for infection was isolated and identified; 81 of the patients 
were treated with miltefosine, in whom 30 (37%) and 51 (63%) of the 
isolated strains were identified as L. (V.) panamensis and L. (V.) braziliensis, 
respectively. Of the group treated with thermotherapy, the strain was 
identified in 83 patients, in whom 24 (29%) and 59 (71%) of the strains 
were L. (V.) panamensis and L. (V.) braziliensis, respectively.
Cure rates in the miltefosine group were 60% for L. (V.) panamensis 
and 49% for L. (V.) braziliensis. The cure rate for the thermotherapy 
group was 58% for L. (V.) panamensis and 53% for L. (V.) braziliensis. 
No significant difference was found for treatment efficacy between the 
species responsible for infection (miltefosine p = 0.3, thermotherapy 
p = 0.6).
Also, there was no association found between treatment efficacy 
and characteristics, such as number, anatomical location, lesion type, or 
geographical location in Colombia where the infection occurred (Table 3). 
Recurrence: Three (2.1%) and six (4.1%) of the patients treated with 
miltefosine and thermotherapy, respectively, had recurrences. 
Safety: Localized and systemic adverse events seen in our study are 
summarized in Table 4.
Mid-way through treatment, miltefosine was associated with a greater 
occurrence of headache, vomiting, nausea, and anorexia, and at the end 
of treatment with a greater frequency of myalgia, arthralgia, headache, 
vomiting, nausea, and anorexia. Thermotherapy was associated with pain 
at the lesion site following the application of treatment.
We were able to determine that there is no association of either of the 
two treatments with changes in renal (Creatinine and BUN), hepatic (AST 
and ALT), and blood (hemoglobin, hematocrit, erythrocytes, leukocytes, 
and platelets) tests, neither mid-way through the treatment nor at the 
end. However, the proportion of changes in lab results for hepatic and 
pancreatic tests was greater in the miltefosine group.
Serious adverse events: One volunteer from the miltefosine group 
developed hematemesis, which was medically treated until the patient’s 
recovery.Fig. 1 - Flow diagram of the volunteer study participants.
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Table 1






















Weight (Kg) (Median [min - max] ) 64 (47 - 90) 65 (42 - 104) 0.8†
















Number of lesions (%)**
1 





















Evolution time (days) (Median [min – max] ) 60 (15 - 1080) 85 (10 - 690) 0.7†
Species (%) 
L. (V.) panamensis 






* Chi square test; † Mann Whitney test; ‡ person who is born from one white parent and one indian parent; § person who is born from one white parent and one black 
parent; ** According to number of lesions;# This category includes 18 volunteers who presented with lesions to the upper and lower body; 8 and 10 from the miltefosine 
and thermotherapy groups, respectively 
Table 2




Cure / Total Efficacy (%) CI 95% Cure / Total Efficacy (%) CI 95%
Intention to treat 85/145 59 (50 - 67) 86/149 58 (49 - 66) 0.9
By protocol 85/122 70 (61 - 78) 86/134 64 (55 - 73) 0.4
*Chi square test.
Survival analysis: The time free of disease for both treatments is 
shown in Figure 2. No difference was found between the cumulative 
survival rates of patients who received miltefosine and those who received 
thermotherapy (p = 0.2). 
DISCUSSION
The efficacy of miltefosine, 70% by intention to treat and 59% per 
protocol, differs with previous studies conducted in Colombia where 
the efficacy of the protocol was 91%, but it is similar to that found in 
Guatemala where it was 53%22.
The differences in therapeutic response in the previous study in 
Colombia and Guatemala were attributed to the species of Leishmania 
predominant in each country22. The data for Colombia, however, was 
mainly based on historical records, given that only seven isolated strains 
were identified in the study from the 73 study participants, and all were 
identified as L. (V.) panamensis. In this study, we included a larger number 
of patients than previous studies. Additionally, both species of Leishmania 
causing the majority of leishmaniasis cases in the country were present, 
and there were no significant differences in treatment response between 
the species responsible for the infection. However, we did observe a 
decreased therapeutic response in patients with L. (V.) braziliensis, of 
whom 49% were cured versus 53% of patients with L. (V.) panamensis. 
A similar situation was observed for thermotherapy treatment.
Thermotherapy showed an efficacy of 58% and 64% in the analysis by 
intention to treat and by protocol, respectively. This result was comparable 
to that obtained in Kabul, Afghanistan, where the efficacy by protocol 
was found to be 69.4%19 and less than that found in other studies where 
localized heat was applied in various dosages.
The Thermomed® equipment gives and maintains localized heat of 
50 degrees Celsius at the application site1 and has the advantage of being 
completed in one to four sessions, decreasing the adherence problems 
faced by other treatments. Also, it does not have systemic side effects, so 
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Table 3

















































** Chi square test; † This category includes 18 volunteers who presented with lesions on the upper and lower parts of the body; 8 and 10 from the 
miltefosine and thermotherapy groups, respectively.
Table 4





Event or Test/Total volunteers (%) RR (CI 95%)









Fever 8/130 (6) 4/124 (3.22%) 1.91 (0.59 - 6.18) 8/129 (6) 4/132 (3) 2.05 (0.63 – 6.63)
Myalgia 9/130 (7) 3/124 (2.41%) 2.86 (0.79 - 10.33) 16/129 (12) 4/132 (3) 4.1 (1.41 – 11.91)*
Arthralgia 9/130 (7) 3/124 (2.41%) 2.86 (0.79 - 10.33) 13/129 (10) 3/132 (2) 4.43 (1.29 – 15.2)*
Headache 23/130 (18) 10/124 (8.1%) 2.19 (1.09 - 4.42) 30/129 (23) 13/132 (10) 2.36 (1.29 – 4.32)*
Vomiting 29/130 (22) 3/124 (2.41%) 9.22 (2.88 - 29.50)** 44/129 (34) 2/132 (2) 22.51 (5.57 – 90.9)**
Nausea 38/130 (29) 5/124 (4.03%) 7.25 (2.95 - 17.82)** 59/129 (46) 4/132 (3) 15.1 (5.65 – 40.34)**
Anorexia 19/130 (11) 5/124 (4.03%) 3.62 (1.40 - 9.41)* 37/129 (29) 6/132 (5) 6.31 (2.76 – 14.44)**
Diarrhea 0/130 (0) 0/124 (0%) - 6/129 (5) 1/132 (2) 6.14 (0.75 – 50.29)
Abdominal pain 0/130 (0) 0/124 (0) - 9/129 (7) 0/132 (0) -
Lesion pain 14/130 (9) 27/124 (22) 11/129 (9) 18/132 (14) 0.63 (0.31 – 1.27)
Lesion infection 5/130 (4) 9/124 (7) 0.53 (0.18 - 1.54) 5/129 (4) 11/132 (8) 0.47 (0.17 – 1.3)
Lesion vesicles 0/130 (0) 4/124 (3) - 0/129 (0) 5/132 (4) -










↑ Creatinine - - - 1/103 (2) 0/80 (0) -
↑ BUN - 1/83 (2) - 3/103 (3) 2/80 (3) 1.17 (0.2 – 6.81)
↑ AST 1/114 (2) 1/93 (2) 0.82 (0.05 - 12.98) 5/103 (5) 2/75 (2.67) 1.82 (0.36 – 9.13)
↑ ALT 1/114 (2) 1/93 (2) 0.82 (0.05 - 12.87) 10/104 (10) 5/73 (6.84) 1.4 (0.5 – 3.94)






y ↓ Hemoglobin - - - 1/102 (2) 1/78 (1.28) 0.76 (0.05 – 12.04)
↓ Erythrocytes 1/105 (2) 4/82 (5) 0.20 (0.02 - 1.71) 1/102 (2) 1/75 (1.33) 0.74 (0.05 – 11.57)
↓ Leukocytes 2/115 (2) 0/96 (0) - 1/105 (2) 0/79 (0) -
↓ Platelets - - - - 1/79 (1.27) -
* < 0.05; ** < 0.001.
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it does not require paraclinical analysis, patients need not be in treatment 
or in convalescence for extended periods of time, and it can also be 
used in patients with renal, hepatic, or cardiac alterations, as well as in 
women who are pregnant, breastfeeding, or of child-bearing age, all of 
whom are disqualified from conventional treatment with pentavalent 
antimonials or miltefosine.
In addition, ethno-medical studies in indigenous and farming 
communities in Latin America show extensive and empirical use 
of locally applied caustic agents (gunpowder, hot sugar cane, silver 
nitrate, petroleum, and battery acid) or cauterization with hot metallic 
instruments, such as spoons or the edge of an ax, which they apply over 
the lesions, achieving, in many cases, lesion scarring14,33,34. 
The association between miltefosine and gastrointestinal adverse 
events, such as nausea, vomiting, anorexia, abdominal pain, and diarrhea, 
reported in previous studies was confirmed24,32. With respect to safety in 
the thermotherapy group, the only reported adverse event was pain at the 
site of heat application, which was controlled with common analgesics 
and did not persist for longer than one week after heat application.
In India, Miltefosine is the first oral agent that has shown a good 
efficacy for the treatment of visceral leishmaniasis caused by L. (L.) 
donovani, or Kala-azar. However, it´s use for CL treatment in the New 
World is limited. Some of its inconveniences are as follows: current cost 
(about 670 USD), which is greater than that of antimonials, long treatment 
period (28 days) leading to adherence problems, lack of adherence leading 
to strain resistance, teratogenicity, which complicates its administration 
to women of child-bearing age because adequate contraception must 
be guaranteed during treatment and up to three months after treatment, 
gastrointestinal adverse effects in over 30% of patients, and finally, as 
seen in this study, efficacy inferior to that of pentavalent antimonials, 
which continue to have an efficacy rate of 85.1% in Colombia32.
The results of this study show that the efficacy of thermotherapy in 
single doses is similar to that of oral miltefosine with a duration of 28 days 
for the treatment of CL in Colombia (p = 0.9), and its toxicity is lower.
One of the criticisms against the use of local therapy in the treatment of 
patients with CL caused by species of the Viannia subgenre is the possibility 
of developing ML. In the case of Colombia, the necessity for prescribing 
systemic treatment to all patients is debatable, given that the incidence of 
ML in the country is less than 0.5%, despite the fact that the great majority 
of patients with CL who reside in rural areas far away from a health care 
center are empirically treated with caustic agents. In these populations, 
it is estimated that only 10% of patients with CL receive treatment with 
antimonials, and even then, the incidence of ML is very low. In addition, 
systemic treatment does not guarantee the absence of ML14,33,34,35. 
However, the cure rate seen in our study with one dose of 
thermotherapy is not sufficiently large enough to recommend it as 
treatment. In the clinical studies where greater cure rates have been seen, 
the patients received two or three heat therapy sessions.
We believe that further clinical studies should be conducted with 
thermotherapy using an increased number of heat application sessions 
or in combination with other local medications.
In American CL, the dissemination of parasites through the 
lymphatic system happens early at the beginning of the lesion. In patients 
with less than three months of disease evolution, 90% present with 
lymphadenopathies; however, ML cases are rare. In any case, all local 
treatments should be accompanied by patient education regarding early 
detection of lesion reactivation signs and possible mucosal complications 
so that they may consult their physician and reserve systemic treatments 
for these cases.
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RESUMEN
Termoterapia efectiva y más segura que la miltefosina en el 
tratamiento de la leishmaniasis cutánea en Colombia
En Colombia antimoniales pentavalentes y miltefosina son 
los medicamentos de primera elección para el tratamiento de la 
leishmaniosis cutánea; sin embargo, su toxicidad, duración (que lleva 
a problemas de adherencia), costo y la disminución de la sensibilidad 
de los parásitos a los mismos, hacen necesaria la búsqueda de nuevas 
alternativas de tratamiento para la leishmaniosis cutánea americana. A 
partir de resultados derivados de un ensayo clínico controlado abierto, 
Fig. 2 - Cumulative survival estimates for absence of disease for each treatment.
LÓPEZ, L.; CRUZ, C.; GODOY, G.; ROBLEDO, S.M. & VÉLEZ, I.D. - Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia. Rev. 
Inst. Med. Trop. Sao Paulo, 55(3): 197-204, 2013.
203
aleatorizado, fase III, se comparó la eficacia y seguridad de la miltefosina 
con la de la termoterapia, para el tratamiento de la leishmaniosis 
cutánea en Colombia. Adultos pertenecientes al Ejército de Colombia 
participaron el estudio. Miltefosina, una cápsula de 50 mg tres veces 
día durante 28 días, vía oral (n = 145). Termoterapia (Thermomed®) 
aplicación de 50 ºC/30´´ sobre la lesión y el área circundante (n = 149). 
Ambos grupos fueron comparables en características sociodemográficas, 
clínicas y parasitológicas. Eficacia de la miltefosina por protocolo 70% 
(85/122 pacientes) y 69% (85/145 pacientes) por intención a tratar. 
Termoterapia eficacia por protocolo 64% (86/134 pacientes) y 58% 
(86/149 pacientes) por intención a tratar. En miltefosina los eventos 
adversos fueron principalmente de tipo gastrointestinal y en termoterapia 
se encontró dolor en el sitio de la lesión luego del tratamiento. En 
el análisis de eficacia (intención a tratar y protocolo) no se encontró 
diferencia estadísticamente significativa entre los tratamientos evaluados. 
ClinicalTrials.gov: NCT00471705.
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